# Synthetic Design Lab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synthetic-design-lab

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.syntheticdesignlab.com
- Total disclosed funding: $10M
- Latest round: Seed (Jan 5, 2024)
- Investors on record: 2

## About

Synthetic Design Lab is focused on advancing cancer treatment through its proprietary SYNTHBODY therapeutic platform, designed to enhance the delivery of antibody-drug conjugates (ADCs) for improved efficacy.Synthetic Design Lab develops innovative therapeutic solutions specializing in enhanced antibody-drug conjugates (ADCs). Founded in 2025 in San Francisco, US, the company has completed one deal as of April 23, 2025, raising a total of USD 20.00 mn in Seed funding from investors including Godfrey Capital and Playground Ventures. The company was founded by individuals with significant backgrounds in biotechnology and healthcare, enhancing its capabilities in the sector.Synthetic Design Lab specializes in the development of its proprietary SYNTHBODY therapeutic platform, engineered to enhance the targeted delivery of antibody-drug conjugates (ADCs) by delivering payloads at least ten times more effectively than existing ADCs. This innovative technology optimizes the precision of drug delivery to specific cells, addressing various cancer indications. The company focuses on integrating biological and biophysical principles into the engineering of ADCs, thereby setting a new standard for their design and application. The primary end-users of SYNTHBODY include cancer patients and healthcare professionals in oncology, with the company aiming to bring its first therapies into clinical trials to validate the efficacy and safety of its products. Synthetic Design Lab's products are marketed primarily in North America and Europe, targeting a range of healthcare providers and research institutions engaged in cancer treatment.Synthetic Design Lab generates revenue through partnerships and collaborations within the biotechnology sector, particularly focused on research and clinical development. The company structures its transactions primarily through B2B arrangements, including partnerships with pharmaceutical firms and research organizations that utilize their SYNTHBODY platform in drug development initiatives. Revenue is generated as these partners engage in joint ventures to develop and commercialize novel ADC therapies, leveraging the proprietary capabilities of SYNTHBODY. This model allows for shared investment in clinical trials and product development, ensuring that both parties benefit from the successful advancement of therapeutic candidates. The company’s flagship product, SYNTHBODY, is expected to play a central role in these transactional structures as it progresses toward initial clinical trials and subsequent commercialization.In April 2025, Synthetic Design Lab raised USD 20.00 mn in Seed funding co-led by Playground Ventures and Godfrey Capital, which will be utilized to accelerate its first therapeutic clinical trials in the upcoming year. The company is actively designing new products within the SYNTHBODY platform to advance cancer treatment options and plans to expand its reach into new markets, specifically targeting Europe and Asia by 2026.

## Funding rounds

- Seed, Jan 5, 2024, $10M — Playground Ventures, Godfrey Capital

## Investors

- Playground Ventures (https://capitalatlas.ai/funds/playground-ventures) — Seed
- Godfrey Capital — Seed